Johnson & Johnson (JNJ) Share-based Compensation Growth (5y) (2014 - 2026)

Johnson & Johnson (JNJ) Share-based Compensation Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Mar 29, 2026 -0.46%
Dec 28, 2025 14.07%
Sep 28, 2025 6.27%
Jun 29, 2025 4.69%
Mar 30, 2025 1.83%
Dec 29, 2024 8.27%
Sep 29, 2024 3.78%
Jun 30, 2024 1.66%
Mar 31, 2024 3.20%
Dec 31, 2023 2.67%
Oct 1, 2023 4.11%
Jul 2, 2023 4.13%
Apr 2, 2023 2.69%
Jan 1, 2023 1.34%
Apr 3, 2022 3.95%
Apr 4, 2021 8.41%
Sep 27, 2020 4.75%
Jun 28, 2020 3.84%
Mar 29, 2020 5.21%
Dec 29, 2019 1.85%